7 studies were found.

1.		Not yet recruiting	BCX-1777 in Treating Patients With Recurrent or Refractory Advanced T-Cell Leukemia or T-Cell Lymphoma Conditions: acute leukemia; adult T-cell leukemia and lymphoma; childhood lymphoblastic lymphoma; Non-Hodgkin's Lymphoma; Prolymphocytic Leukemia
2.		No longer recruiting	BCX-1777 in Treating Patients With Refractory Cancer Conditions: central nervous system cancer; female reproductive cancer; Gastrointestinal Cancer; hematopoietic and lymphoid cancer; skin tumor
3.		No longer recruiting	BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma Conditions: Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome
4.		No longer recruiting	BCX-1777 in Treating Patients With Refractory Hematologic Cancer Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
5.		Recruiting	Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients with Advanced T-Cell Leukemia Condition: Leukemia, T-Cell
6.		Recruiting	Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas Conditions: Leukemia, Lymphocytic; Lymphoma
7.		Completed	A Study of Peldesine (BCX-34) in HIV-Infected Patients Condition: HIV Infections